The European Patent Office (EPO) has revealed its intention to grant a patent covering the CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 June 2021 The University of California Berkeley has sold a non-fungible token based on patent disclosures for Nobel Prize-winning cancer immunotherapies research at an online auction, netting approximately $54,360 from the sale.
1 June 2021 A non-fungible token for a Nobel Prize-winning cancer immunotherapy invention has been minted ahead of an auction tomorrow arranged by the University of California, Berkeley.
25 May 2021 The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.